Gowan Acquires Zoxamide Rights

Avatar for Matt Hopkins By Andrea Klosterman Harris|22 July 2008

“Due to the press of competing priorities for new product development, Dow AgroSciences, as a research-based company, has not been able to devote the time and resources needed to position zoxamide for optimal growth,” said David Hindes, global business leader, fungicides. “We believe that zoxamide will be better positioned with Gowan, where it represents a better strategic fit with the company’s portfolio and general business direction.”

Advertisement

Hide picture